Androgen deprivation--continuous, intermittent, or none at all?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. The RARγ Oncogene: An Achilles Heel for Some Cancers.International journal of molecular sciences · 2021
   Review
2. Retinoic acid receptor γ is a therapeutically targetable driver of growth and survival in prostate cancer.Cancer reports (Hoboken, N.J.) · 2020
   Article
3. Trial Watch: DNA vaccines for cancer therapy.Oncoimmunology · 2014
   Review
4. Current clinical challenges in prostate cancer.Translational andrology and urology · 2013
   Review
5. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.OncoTargets and therapy · 2013
   Article

Corrections and comments

• Comment on
  Intermittent androgen suppression for rising PSA level after radiotherapy.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as